Capital Performance Advisors’s Avita Medical RCEL Stock Holding History

Capital Performance Advisors’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1	Closed	-$11	–	2085
2024 Q3	$11	Buy	+1	New	+$9	﹤0.01%	2880

Other funds holding RCEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Performance Advisors's RCEL Position: Q4 2024 in Review

Capital Performance Advisors sold out of Avita Medical (RCEL) in Q4 2024, closing a stake of 1 share — an estimated $11 sold.

Capital Performance Advisors first reported a position in RCEL in Q3 2024 and held it in 1 quarter. The position peaked at $11 in Q3 2024. 73 funds tracked by Wall St. Rank hold RCEL as of Q4 2024.

Capital Performance Advisors reported no remaining Avita Medical position as of Q4 2024 after selling out during the quarter.
Capital Performance Advisors sold 1 Avita Medical share in Q4 2024, an estimated $11.
Capital Performance Advisors first reported a position in Avita Medical in Q3 2024 and held it in 1 quarter.
Capital Performance Advisors's Avita Medical position peaked at $11 in Q3 2024.
73 funds tracked by Wall St. Rank held Avita Medical as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.